胃腸治療市場機會、成長動力、產業趨勢分析及 2025 - 2034 年預測

2024 年全球胃腸道治療市場價值為 425 億美元，預計到 2034 年將以 5.9% 的複合年成長率成長至 748 億美元。這一市場擴張很大程度上是由於發炎性腸道疾病 (IBD)、胃食道逆流症 (GERD) 和消化性潰瘍等胃腸道 (GI) 疾病盛行率的上升所致。隨著成年人口的不斷成長，慢性胃腸道疾病的發病率也在上升，從而形成了更大的患者群體，並增加了對專科治療的需求。未經治療的胃腸道疾病可導致嚴重的併發症，包括大腸直腸癌和中毒性巨結腸，尤其是在潰瘍性結腸炎等情況下。這些趨勢凸顯了對有效的長期療法的需求，從而推動了對生物製劑和標靶療法等先進治療方案的需求。

生物製劑和生物相似藥的開發在加速市場成長方面發揮了關鍵作用。這些療法已被證明能夠有效治療胃腸道疾病，透過標靶治療控制發炎並幫助維持長期緩解。研發投入的增加以及監管部門的持續核准推動了該領域的創新。此外，公眾對胃腸道健康的認知不斷提高、診斷工具的進步以及新興經濟體醫療保健涵蓋範圍的擴大，使得這些療法更容易被更廣泛的人群所接受，從而進一步支持了市場成長。

2024年，生物製劑和生物相似藥市場規模達196億美元，預計2034年將達到361億美元，複合年成長率為6.4%。這些療法已成為治療克隆氏症和潰瘍性結腸炎等疾病的首選方案。生物製劑提供了一種針對性的發炎控制方法，而生物相似藥則透過降低治療成本，增加了這些療法的可及性，使全球患者能夠負擔得起。近期，關鍵藥物的生物相似藥獲批，進一步促進了先進療法的可及性。

2024年，成人市場規模達263億美元，預計將維持主導地位，2034年複合年成長率達5.6%。成年人口尤其容易罹患慢性胃腸道疾病，例如克隆氏症、潰瘍性結腸炎、胃食道逆流（GERD）和其他相關疾病。盛行率的上升很大程度上是由現代生活方式因素造成的，例如不良的飲食選擇、高壓力水平和久坐習慣，所有這些都會導致需要長期醫療照護的胃腸道問題增加。為了滿足日益成長的需求，製藥公司正在推進標靶藥物製劑和給藥方法的開發，包括注射和緩釋片，旨在提高治療效果並增強患者依從性。

北美胃腸道治療市場在2024年達到178億美元，預計2034年將達到307億美元，複合年成長率為5.6%。北美強大的市場地位得益於其先進的醫療基礎設施、對消化系統健康的高度重視以及現代治療方案的廣泛可及性。領先製藥公司的湧現以及持續的創新和研發投入，持續推動市場的發展。生物技術公司與研究機構之間的合作夥伴關係進一步加速了新型療法的開發和應用，確保北美在全球胃腸道治療市場中繼續保持關鍵地位。

參與全球胃腸道治療市場的知名公司包括武田製藥、葛蘭素史克、禮來公司、強生、西普拉、阿斯特捷利康、百健、輝瑞、拜耳、賽諾菲、太陽製藥、艾伯維、Phathom Pharmaceuticals 和雷迪博士實驗室。胃腸道治療市場的領先公司正致力於透過生物製劑和生物相似藥的創新來擴大其產品組合。許多公司正在投資尖端研究，以開發更有效的治療方法來解決胃腸道疾病的根本原因。與研究機構和生技公司的合作也是加速藥物開發和商業化的常見策略。此外，公司正優先考慮地理擴張，特別是在新興市場，透過使治療更容易獲得和負擔得起。

目錄

第1章：方法論與範圍

第2章：執行摘要

第3章：行業洞察

• 產業生態系統分析
  • 供應商格局
  • 每個階段的增值
  • 影響價值鏈的因素
• 產業衝擊力
  • 成長動力
    • 胃腸道疾病盛行率上升
    • 藥物研發不斷取得進展
    • 提高胃腸道健康意識和預防保健措施
    • 增加研發投入和活動
  • 產業陷阱與挑戰
    • 藥物的不良反應
  • 市場機會
    • 人們對腸道微生物組研究的興趣日益濃厚
    • 數位健康平台正在改善胃腸道治療的可近性
• 成長潛力分析
• 管道分析
• 監管格局
• 未來市場趨勢
• 波特的分析
• PESTEL分析

第4章：競爭格局

• 介紹
• 公司矩陣分析
• 公司市佔率分析
• 主要市場參與者的競爭分析
• 競爭定位矩陣
• 關鍵進展
  • 併購
  • 夥伴關係和合作
  • 擴張計劃

第5章：市場估計與預測：按藥物類型，2021 - 2034 年

• 主要趨勢
• 止瀉藥
• 瀉藥
• 生物製劑/生物相似藥
• 止吐藥
• 抗潰瘍藥
• 抗生素
• 抗酸藥
• 質子幫浦抑制劑（PPI）
• 其他藥物類型

第6章：市場估計與預測：依疾病類型，2021 - 2034 年

• 主要趨勢
• 發炎性腸道疾病（IBD）
  • 克隆氏症
  • 潰瘍性結腸炎
• 胃食道逆流症（GERD）
  • 第一階段
  • 第 2 階段
  • 第 3 階段
  • 第四階段
• 消化性潰瘍病
• 腸躁症（IBS）
  • 腸躁症（IBS）
  • 腸躁症（IBS）
  • 腸躁症
• 其他疾病類型

第7章：市場估計與預測：按藥物類型，2021 - 2034 年

• 主要趨勢
• 品牌
• 泛型

第8章：市場估計與預測：按年齡層，2021 - 2034 年

• 主要趨勢
• 兒科
• 成人
• 老年

第9章：市場估計與預測：按管理路線，2021 - 2034 年

• 主要趨勢
• 口服
• 腸外

第 10 章：市場估計與預測：按配銷通路，2021 年至 2034 年

• 主要趨勢
• 醫院藥房
• 零售藥局
• 網路藥局

第 11 章：市場估計與預測：按地區，2021 年至 2034 年

• 主要趨勢
• 北美洲
  • 美國
  • 加拿大
• 歐洲
  • 德國
  • 英國
  • 法國
  • 西班牙
  • 義大利
  • 荷蘭
• 亞太地區
  • 中國
  • 日本
  • 印度
  • 澳洲
  • 韓國
• 拉丁美洲
  • 巴西
  • 墨西哥
  • 阿根廷
• 中東和非洲
  • 南非
  • 沙烏地阿拉伯
  • 阿拉伯聯合大公國

第12章：公司簡介

• AbbVie
• AstraZeneca
• Bayer
• Biogen
• Cipla
• Dr. Reddy's Laboratories
• Eli Lilly and Company
• GlaxoSmithKline
• Glenmark Pharmaceuticals
• Johnson & Johnson
• Novo Nordisk
• Pfizer
• Phathom Pharmaceuticals
• Sanofi
• Sun Pharma
• Takeda Pharmaceutical

The Global Gastrointestinal Therapeutics Market was valued at USD 42.5 billion in 2024 and is estimated to grow at a CAGR of 5.9% to reach USD 74.8 billion by 2034. This market expansion is largely driven by the rising prevalence of gastrointestinal (GI) disorders, such as inflammatory bowel disease (IBD), gastroesophageal reflux disease (GERD), and peptic ulcer disease. As the adult population continues to expand, the incidence of chronic GI conditions is also on the rise, creating a larger patient base and increasing demand for specialized treatments. Untreated GI conditions can lead to severe complications, including colorectal cancer and toxic megacolon, particularly in cases like ulcerative colitis. These trends highlight the need for effective, long-term therapies, fueling the demand for advanced treatment options such as biologics and targeted therapies.

The development of biologics and biosimilars has played a critical role in accelerating market growth. These therapies have proven to be highly effective in managing GI disorders by providing targeted treatments that control inflammation and help maintain long-term remission. Increased investment in research and development (R&D), along with a steady stream of regulatory approvals, has driven innovation in the field. Additionally, improved public awareness of GI health, advancements in diagnostic tools, and the expansion of healthcare access in emerging economies have made these treatments more available to a broader population, further supporting market growth.

The biologics and biosimilars segment was valued at USD 19.6 billion in 2024 and is expected to reach USD 36.1 billion by 2034, growing at a CAGR of 6.4%. These treatments have become the preferred option for managing conditions like Crohn's disease and ulcerative colitis. Biologics offer a targeted approach to inflammation control, while biosimilars have increased access to these therapies by lowering the cost of treatment, making them more affordable for patients worldwide. The recent approval of biosimilars for key drugs has further contributed to the growing accessibility of advanced treatments.

In 2024, the adult segment generated USD 26.3 billion and is projected to maintain its dominant position, growing at a CAGR of 5.6% through 2034. The adult population is especially vulnerable to chronic gastrointestinal (GI) conditions like Crohn's disease, ulcerative colitis, GERD, and other related disorders. This increased prevalence is largely driven by modern lifestyle factors, such as poor dietary choices, high stress levels, and sedentary habits, all of which contribute to a rise in GI issues that require long-term medical care. To meet the growing demand, pharmaceutical companies are advancing the development of targeted drug formulations and delivery methods, including injectables and sustained-release tablets, aimed at improving treatment efficacy and enhancing patient compliance.

North America Gastrointestinal Therapeutics Market generated USD 17.8 billion in 2024 and is expected to generate USD 30.7 billion by 2034, growing at a CAGR of 5.6%. North America's strong market position is attributed to its advanced healthcare infrastructure, high awareness of digestive health, and widespread access to modern treatment options. The presence of leading pharmaceutical companies, along with ongoing innovation and research efforts, continues to drive the market. Collaborative partnerships between biotech firms and research institutions further accelerate the development and availability of novel therapies, ensuring that North America remains a key player in the global GI therapeutics market.

Notable companies involved in the Global Gastrointestinal Therapeutics Market include Takeda Pharmaceutical, GlaxoSmithKline, Eli Lilly and Company, Johnson & Johnson, Cipla, AstraZeneca, Biogen, Pfizer, Bayer, Sanofi, Sun Pharma, AbbVie, Phathom Pharmaceuticals, and Dr. Reddy's Laboratories. Leading companies in the gastrointestinal therapeutics market are focusing on expanding their product portfolios through innovation in biologics and biosimilars. Many are investing in cutting-edge research to develop more effective treatments that address the underlying causes of GI disorders. Partnerships with research institutions and biotech firms are also a common strategy to accelerate drug development and commercialization. Additionally, companies are prioritizing geographical expansion, particularly in emerging markets, by making treatments more accessible and affordable.

Table of Contents

Chapter 1 Methodology and Scope

• 1.1 Market scope and definition
• 1.2 Research design
  • 1.2.1 Research approach
  • 1.2.2 Data collection methods
• 1.3 Data mining sources
  • 1.3.1 Global
  • 1.3.2 Regional/Country
• 1.4 Base estimates and calculations
  • 1.4.1 Base year calculation
  • 1.4.2 Key trends for market estimation
• 1.5 Primary research and validation
  • 1.5.1 Primary sources
• 1.6 Forecast model
• 1.7 Research assumptions and limitations

Chapter 2 Executive Summary

• 2.1 Industry 360⁰ synopsis
• 2.2 Key market trends
  • 2.2.1 Regional
  • 2.2.2 Drug type
  • 2.2.3 Disease type
  • 2.2.4 Medication type
  • 2.2.5 Age group
  • 2.2.6 Route of administration
  • 2.2.7 Distribution channel
• 2.3 CXO perspectives: Strategic imperatives
  • 2.3.1 Key decision points for industry executives
  • 2.3.2 Critical success factors for market players
• 2.4 Future outlook and strategic recommendations

Chapter 3 Industry Insights

• 3.1 Industry ecosystem analysis
  • 3.1.1 Supplier landscape
  • 3.1.2 Value addition at each stage
  • 3.1.3 Factor affecting the value chain
• 3.2 Industry impact forces
  • 3.2.1 Growth drivers
    • 3.2.1.1 Rising prevalence of gastrointestinal diseases
    • 3.2.1.2 Growing advancements in drug development
    • 3.2.1.3 Increasing awareness and preventive care measures for gastrointestinal health
    • 3.2.1.4 Increased R&D investment and activities
  • 3.2.2 Industry pitfalls and challenges
    • 3.2.2.1 Adverse effects of medication
  • 3.2.3 Market opportunities
    • 3.2.3.1 Growing interest in gut microbiome research
    • 3.2.3.2 Digital health platforms are improving access to GI treatments
• 3.3 Growth potential analysis
• 3.4 Pipeline analysis
• 3.5 Regulatory landscape
• 3.6 Future market trends
• 3.7 Porter’s analysis
• 3.8 PESTEL analysis

Chapter 4 Competitive Landscape, 2024

• 4.1 Introduction
• 4.2 Company matrix analysis
• 4.3 Company market share analysis
• 4.4 Competitive analysis of major market players
• 4.5 Competitive positioning matrix
• 4.6 Key developments
  • 4.6.1 Mergers and acquisitions
  • 4.6.2 Partnerships and collaborations
  • 4.6.3 Expansion plans

Chapter 5 Market Estimates and Forecast, By Drug Type, 2021 - 2034 ($ Mn)

• 5.1 Key trends
• 5.2 Antidiarrheals
• 5.3 Laxatives
• 5.4 Biologics/ biosimilars
• 5.5 Antiemetics
• 5.6 Antiulcer agents
• 5.7 Antibiotics
• 5.8 Antacids
• 5.9 Proton pump inhibitors (PPIs)
• 5.10 Other drug types

Chapter 6 Market Estimates and Forecast, By Disease Type, 2021 - 2034 ($ Mn)

• 6.1 Key trends
• 6.2 Inflammatory bowel disease (IBD)
  • 6.2.1 Crohn's disease
  • 6.2.2 Ulcerative colitis
• 6.3 Gastroesophageal reflux disease (GERD)
  • 6.3.1 Stage 1
  • 6.3.2 Stage 2
  • 6.3.3 Stage 3
  • 6.3.4 Stage 4
• 6.4 Peptic ulcer disease
• 6.5 Irritable bowel syndrome (IBS)
  • 6.5.1 IBS-D
  • 6.5.2 IBS-C
  • 6.5.3 IBS-M
• 6.6 Other disease types

Chapter 7 Market Estimates and Forecast, By Medication Type, 2021 - 2034 ($ Mn)

• 7.1 Key trends
• 7.2 Branded
• 7.3 Generics

Chapter 8 Market Estimates and Forecast, By Age Group, 2021 - 2034 ($ Mn)

• 8.1 Key trends
• 8.2 Pediatric
• 8.3 Adult
• 8.4 Geriatric

Chapter 9 Market Estimates and Forecast, By Route of Administration, 2021 - 2034 ($ Mn)

• 9.1 Key trends
• 9.2 Oral
• 9.3 Parenteral

Chapter 10 Market Estimates and Forecast, By Distribution Channel, 2021 - 2034 ($ Mn)

• 10.1 Key trends
• 10.2 Hospital pharmacies
• 10.3 Retail pharmacies
• 10.4 Online pharmacies

Chapter 11 Market Estimates and Forecast, By Region, 2021 - 2034 ($ Mn)

• 11.1 Key trends
• 11.2 North America
  • 11.2.1 U.S.
  • 11.2.2 Canada
• 11.3 Europe
  • 11.3.1 Germany
  • 11.3.2 UK
  • 11.3.3 France
  • 11.3.4 Spain
  • 11.3.5 Italy
  • 11.3.6 Netherlands
• 11.4 Asia Pacific
  • 11.4.1 China
  • 11.4.2 Japan
  • 11.4.3 India
  • 11.4.4 Australia
  • 11.4.5 South Korea
• 11.5 Latin America
  • 11.5.1 Brazil
  • 11.5.2 Mexico
  • 11.5.3 Argentina
• 11.6 Middle East and Africa
  • 11.6.1 South Africa
  • 11.6.2 Saudi Arabia
  • 11.6.3 UAE

Chapter 12 Company Profiles

• 12.1 AbbVie
• 12.2 AstraZeneca
• 12.3 Bayer
• 12.4 Biogen
• 12.5 Cipla
• 12.6 Dr. Reddy’s Laboratories
• 12.7 Eli Lilly and Company
• 12.8 GlaxoSmithKline
• 12.9 Glenmark Pharmaceuticals
• 12.10 Johnson & Johnson
• 12.11 Novo Nordisk
• 12.12 Pfizer
• 12.13 Phathom Pharmaceuticals
• 12.14 Sanofi
• 12.15 Sun Pharma
• 12.16 Takeda Pharmaceutical